Maintenance of benefit after 8-week and 52-week treatment with atomoxetine hydrochloride in adolescents with ADHD

Trial Profile

Maintenance of benefit after 8-week and 52-week treatment with atomoxetine hydrochloride in adolescents with ADHD

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Dec 2009

At a glance

  • Drugs Atomoxetine (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Dec 2009 Results published in the Journal of Child and Adolescent Psychiatry.
    • 13 Dec 2006 Status change
    • 28 Jul 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top